医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GN MEDI Antibacterial Spray Launched to End COVID-19 Crisis and Solve the Shortage of Masks

2020年04月07日 PM05:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

GN COS launched GN MEDI 99.9% antibacterial spray which is an eco-friendly and odorless product containing harmless minerals for sterilization and disinfection.

The antibacterial spray received IR52 Jang Young-shil Awards hosted by MSIT, thanks to its world’s first ‘coating technique with antibacterial mineral’.

GN MEDI 99.9% antibacterial spray eliminates 99.9 percent of pneumococcus, colon bacillus, and staphylococcus aureus. And Korea Testing & Research Institute checked that it sterilized 99.99 percent of Influenza A virus that is the same RNA virus family as COVID-19.

Nationally Authorized Testing- Inspection and Research Institute, KOTITI checked that the masks’ filters worked fine after spraying the antibacterial spray on KF94 masks. They checked filters’ functions under criteria, passing the amount of paraffin oil per minute following the test method of KF masks. It was widely known that KF94 masks usually prevent ninety-four percent.

When KOTITI tested pneumococcus after seventy-two hours from spraying the antibacterial spray on the mask, the mask had maintained 99.9 percent of excellent antibacterial function. The spray also eliminates the offensive smell.

Boram Jung, a marketing team official of GN COS said, “GN MEDI 99.9% antibacterial spray maintains the antibacterial effect for a long time compared to highly volatile ethanol and has an excellent safety unlike chlorine-releasing products causing cancers. Now you can use our spray that passed the skin irritation test for clothing and textile products as well as doorknobs, hand straps on the metro, and elevator buttons.”

The antibacterial spray is also used for sterilization, disinfection, and deodorization and acknowledged by KATRI that they fit for a stability standard of risk-concerned products. The product also received U.S. Food and Drug Administration (FDA) approval in March.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005325/en/

CONTACT

GN COS

Boram Jung

+82-70-4827-4877

bbo0026@gncos.co.kr

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Nerviano Medical Sciences S.r.l.宣布与默克达成包含许可选择权的合作协议
  • CANbridge Pharmaceuticals Data on CAN106 to be Presented at Two Conferences
  • Where is China’s Global Fund Pledge? Asks AHF
  • United Kingdom National Institute for Health and Care Excellence (NICE) Publishes Interventional Procedure Guidance (IPG) for ReActiv8® Restorative Neurostimulation™
  • ブラッド・キャンサー・ディスカバリー誌の論文が患者転帰を改善するエクセンシアのAI精密医療プラットフォームの能力をさらに裏付け